Cyto Wave Technologies
San Francisco
About Cyto Wave Technologies
Cyto Wave Technologies (“The Company”) has licensed a first-in-class breakthrough technology platform from the University of Arkansas for Medical Sciences (UAMS) that allows the early non-invasive detection, capturing and targeted destruction of metastatic circulating tumor cells (CTCs) in vivo The Company is developing a highly-sensitive, portable device (“iV3″) for real-time detection of CTCs directly in the bloodstream of cancer patients. CTCs are detected by a proprietary laser technology and can then be extracted from the bloodstream. The laser can also potentially destroy CTCs directly. iV3 has been funded with US$4.4 million from the National Health Institutes/National Cancer Institute, the Department of Defense (DoD) and private investors which has alleviated much of the early risk associated with developing a new breakthrough technology. A human clinical trial in melanoma patients is currently being initiated.
Company Facts
- Operating status: Closed
- Company type: For Profit
- IPO status: Private
- Employees: 1 – 10
- Total funding: $965.0K
- Last round: Series Unknown (Apr 2013)
- Website: cytowavetech.com
- Phone: 415-494-7850
Industries & Categories
Biotechnology, Health Care, Pharmaceutical
Canonical: https://fsome.com/organization/cyto-wave-technologies-2339872 · For the full interactive profile (charts, investors, team, acquisitions, press), please enable JavaScript.